The DOI matches its Crossref record; 284 of the 284 references it cites were found in a registry or an index.
Crosstalk Between Peroxisome Proliferator-Activated Receptor Gamma and the Canonical WNT/β-Catenin Pathway in Chronic Inflammation and Oxidative Stress During Carcinogenesis
Open accessAbstract
. WNT/β-catenin signaling is upregulated in inflammatory processes and oxidative stress and in many cancers, although there are some exceptions for cancers. The opposite is observed with PPARγ, which is generally downregulated during inflammation and oxidative stress and in many cancers. This helps to explain in part the opposite and unidirectional profile of the canonical WNT/β-catenin signaling and PPARγ in these three frequent and morbid processes that potentiate each other and create a vicious circle. Many intracellular pathways commonly involved downstream will help maintain and amplify inflammation, oxidative stress, and cancer. Thus, many WNT/β-catenin target genes such as c-Myc, cyclin D1, and HIF-1α are involved in the development of cancers. Nuclear factor-kappaB (NFκB) can activate many inflammatory factors such as TNF-α, TGF-β, interleukin-6 (IL-6), IL-8, MMP, vascular endothelial growth factor, COX2, Bcl2, and inducible nitric oxide synthase. These factors are often associated with cancerous processes and may even promote them. Reactive oxygen species (ROS), generated by cellular alterations, stimulate the production of inflammatory factors such as NFκB, signal transducer and activator transcription, activator protein-1, and HIF-α. NFκB inhibits glycogen synthase kinase-3β (GSK-3β) and therefore activates the canonical WNT pathway. ROS activates the phosphatidylinositol 3 kinase/protein kinase B (PI3K/Akt) signaling in many cancers. PI3K/Akt also inhibits GSK-3β. Many gene mutations of the canonical WNT/β-catenin pathway giving rise to cancers have been reported (CTNNB1, AXIN, APC). Conversely, a significant reduction in the expression of PPARγ has been observed in many cancers. Moreover, PPARγ agonists promote cell cycle arrest, cell differentiation, and apoptosis and reduce inflammation, angiogenesis, oxidative stress, cell proliferation, invasion, and cell migration. All these complex and opposing interactions between the canonical WNT/β-catenin pathway and PPARγ appear to be fairly common in inflammation, oxidative stress, and cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–284 of 284
Trombetta, A., Maggiora, M., Martinasso, G., Cotogni, P., Canuto, R. A., & Muzio, G. (2007) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2006.12.014 · Cited by 93
Salganik, R. I., Albright, C. D., Rodgers, J., Kim, J., Zeisel, S. H., Sivashinskiy, M. S., & Dyke, T. A. V. (2000) · Carcinogenesis · doi:10.1093/carcin/21.5.909 · Cited by 93
Drygiannakis, I., Valatas, V., Sfakianaki, O., Bourikas, L. A., Manousou, P., Kambas, K., Ritis, K., Kolios, G. C., & Kouroumalis, E. (2012) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2012.04.008 · Cited by 93
Vallée, A., Vallée, J.-N., Guillevin, R., & Lecarpentier, Y. (2017) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-017-0550-9 · Cited by 93
Self-citationReactive oxygen species: an Achilles’ heel of melanoma?
Fruehauf, J. P., & Trapp, V. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.11.1751 · Cited by 92
Peroxisome Proliferator Activated Receptor-γ (PPAR-γ) Ligands and Angiogenesis
Margeli, A. P., Kouraklis, G. P., & Theocharis, S. E. (2003) · Angiogenesis · doi:10.1023/b:agen.0000021377.13669.c0 · Cited by 89
β-catenin regulates NF-κB activityviaTNFRSF19 in colorectal cancer cells
Schön, S., Flierman, I., Ofner, A., Stahringer, A., Holdt, L. M., Kolligs, F. T., & Herbst, A. (2014) · International Journal of Cancer · doi:10.1002/ijc.28839 · Cited by 87
Calvisi, D. F., Ladu, S., Hironaka, K., Factor, V. M., & Thorgeirsson, S. S. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.07.030 · Cited by 87
Chu, K., Lee, S., Koo, J.-S., Jung, K., Kim, E., Sinn, D.-I., Kim, J., Ko, S., Kim, S., Song, E.-C., et al. (2006) · Brain Research · doi:10.1016/j.brainres.2006.03.114 · Cited by 87
Repression of β-catenin signaling by PPARγ ligands
Lu, D., & Carson, D. A. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.03.010 · Cited by 86
New perspectives on APC control of cell fate and proliferation in colorectal cancer
Phelps, R. A., Broadbent, T. J., Stafforini, D. M., & Jones, D. A. (2009) · Cell Cycle · doi:10.4161/cc.8.16.9278 · Cited by 85
Bishop‐Bailey, D. (2011) · Biochemical Society Transactions · doi:10.1042/bst20110643 · Cited by 85
Vallée, A., Lecarpentier, Y., Guillevin, R., & Vallée, J.-N. (2017) · Journal of Molecular Neuroscience · doi:10.1007/s12031-017-0947-4 · Cited by 83
Self-citationLecarpentier, Y., CLAES, V. A., Vallée, A., & Hébert, J. (2017) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0144-7 · Cited by 80
Self-citationHuang, P., Sata, M., Nishimatsu, H., Sumi, M., Hirata, Y., & Nagai, R. (2007) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2007.06.014 · Cited by 76
Schultze, K., Böck, B. C., Eckert, A., Oevermann, L., Ramacher, D., Wiestler, O. D., & Roth, W. (2006) · APOPTOSIS · doi:10.1007/s10495-006-8896-3 · Cited by 75
Gustafson, B., Eliasson, B., & Smith, U. (2009) · Diabetologia · doi:10.1007/s00125-009-1615-1 · Cited by 74
Schupp, M., Cristancho, A. G., Lefterova, M. I., Hanniman, E. A., Briggs, E. R., Steger, D. J., Qatanani, M., Curtin, J. C., Schug, J., Ochsner, S. A., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809498200 · Cited by 74
Su, W., Kleinhanz, R. R., & Schadt, E. E. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.23 · Cited by 74
Elnemr, A., Ohta, T., Iwata, K., et al. (2000) · International Journal of Oncology · doi:10.3892/ijo.17.6.1157 · Cited by 73
Role of interferon-γ in the evolution of murine bleomycin lung fibrosis
Segel, M. J., Izbicki, G., Cohen, P. Y., Or, R., Christensen, T. G., Wallach‐Dayan, S. B., & Breuer, R. (2003) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00303.2002 · Cited by 73
Emerging role of the β-catenin-PPARγ axis in the pathogenesis of colorectal cancer
Sabatino, L., Pancione, M., Votino, C., Colangelo, T., Lupo, A., Novellino, E., Lavecchia, A., & Colantuoni, V. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i23.7137 · Cited by 72
Covey, T. M., Edes, K., Coombs, G. S., Virshup, D. M., & Fitzpatrick, F. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013545 · Cited by 72
Ajmone‐Cat, M. A., D’Urso, M. C., di Blasio, G., Brignone, M. S., Simone, R. D., & Minghetti, L. (2015) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2015.11.012 · Cited by 72
Onyido, E. K., Sweeney, E., & Nateri, A. S. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0541-3 · Cited by 71
De, P. K., Carlson, J. H., Wu, H., Marcus, A. I., Leyland-Jones, B., & Dey, N. (2016) · Oncotarget · doi:10.18632/oncotarget.8988 · Cited by 70
Protective effect of ascorbic acid in experimental gastric cancer: reduction of oxidative stress
de Oliveira, C. P. M. S. (2003) · World Journal of Gastroenterology · doi:10.3748/wjg.v9.i3.446 · Cited by 69
Pancione, M., Forte, N. R., Sabatino, L., Tomaselli, E., Parente, D., Febbraro, A., & Colantuoni, V. (2009) · Human Pathology · doi:10.1016/j.humpath.2008.08.019 · Cited by 68
Vallée, A., Lecarpentier, Y., Guillevin, R., & Vallée, J.-N. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00352 · Cited by 68
Self-citationHmgb1-IL-23-IL-17-IL-6-Stat3 Axis Promotes Tumor Growth in Murine Models of Melanoma
Tang, Q., Li, J., Zhu, H., Li, P., Zou, Z., & Xiao, Y. (2013) · Mediators of Inflammation · doi:10.1155/2013/713859 · Cited by 67
Ma, B., Zhong, L., van Blitterswijk, C., Post, J. N., & Karperien, M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.453985 · Cited by 65
Lecarpentier, Y., & Vallée, A. (2016) · Frontiers in Neurology · doi:10.3389/fneur.2016.00100 · Cited by 65
Self-citationChen, T. ‐., Chang, S., Huang, C., Wang, K. ‐., Yeh, K., Liu, C., Lee, H., Lin, C., & Cheng, Y. ‐. (2013) · Colorectal Disease · doi:10.1111/codi.12318 · Cited by 64
Zhang, W., & Wu, N. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.8.2887 · Cited by 63
Józkowicz, A., Dulak, J., Piątkowska, E., Placha, W., & Dembinska-Kiec, A. (2000) · Acta Biochimica Polonica · doi:10.18388/abp.2000_3967 · Cited by 63
Battaglia, S., Maguire, O., Thorne, J. L., Hornung, L. B., Doig, C. L., Liu, S., Sucheston, L. E., Bianchi, A., Khanim, F. L., Gommersall, L. M., et al. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq086 · Cited by 63
Ament, Z., Masoodi, M., & Griffin, J. L. (2012) · Genome Medicine · doi:10.1186/gm331 · Cited by 63
Peroxisome proliferator-activated receptors in macrophage biology: friend or foe?
Moore, K. J., Fitzgerald, M. L., & Freeman, M. W. (2001) · Current Opinion in Lipidology · doi:10.1097/00041433-200110000-00007 · Cited by 63
Thermodynamic Aspects and Reprogramming Cellular Energy Metabolism during the Fibrosis Process
Vallée, A., Lecarpentier, Y., & Vallée, J.-N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122537 · Cited by 62
Self-citationAerobic glycolysis in amyotrophic lateral sclerosis and Huntington’s disease
Vallée, A., Lecarpentier, Y., Guillevin, R., & Vallée, J.-N. (2018) · Reviews in the Neurosciences · doi:10.1515/revneuro-2017-0075 · Cited by 62
Self-citationNovel Role of Oxidants in the Molecular Mechanism of Action of Peroxisome Proliferators
Rusyn, I., Rose, M., Bojes, H. K., & Thurman, R. G. (2000) · Antioxidants and Redox Signaling · doi:10.1089/15230860050192350 · Cited by 61
Inhibitory Effects of PPARγ Ligands on TGF-β1–Induced Corneal Myofibroblast Transformation
Jeon, K., Kulkarni, A. A., Woeller, C. F., Phipps, R. P., Sime, P. J., Hindman, H. B., & Huxlin, K. R. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.01.026 · Cited by 61
Saegusa, M., Hashimura, M., Kuwata, T., Hamano, M., & Okayasu, I. (2007) · The Journal of Pathology · doi:10.1002/path.2198 · Cited by 59
Akinyeke, T. O., & Stewart, L. V. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.12.15709 · Cited by 59
Anuja, K., Roy, S., Ghosh, C., Gupta, P., Bhattacharjee, S., & Banerjee, B. (2016) · Inflammation Research · doi:10.1007/s00011-016-0985-3 · Cited by 59
Toyota, M., Miyazaki, Y., Kitamura, S., Nagasawa, Y., Kiyohara, T., Shinomura, Y., & Matsuzawa, Y. (2002) · Life Sciences · doi:10.1016/s0024-3205(01)01524-7 · Cited by 56
Commonalities in the Association between PPARG and Vitamin D Related with Obesity and Carcinogenesis
Bandera-Merchán, B., Tinahones, F. J., & Macías‐González, M. (2016) · PPAR Research · doi:10.1155/2016/2308249 · Cited by 53
Carayol, N., & Wang, C. (2006) · Cellular Signalling · doi:10.1016/j.cellsig.2006.02.014 · Cited by 52
Qian, J., Niu, M., Zhai, X., Zhou, Q., & Zhou, Y. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.06.003 · Cited by 51
Chen, F., & Harrison, L. E. (2004) · Cellular Signalling · doi:10.1016/j.cellsig.2004.11.002 · Cited by 50
Lee, Y., Kim, S. H., Lee, Y. J., Kang, E. S., Lee, B., Soo, B., Kim, J. W., Song, D. H., & Lee, H. C. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1363-8 · Cited by 50
YAN, K.-H., Yao, C., Chang, H., Lai, G., Cheng, A., & Chuang, S. (2009) · Molecular Carcinogenesis · doi:10.1002/mc.20593 · Cited by 48
Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas
Bognar, M., Vincendeau, M., Erdmann, T., Seeholzer, T., Grau, M., Linnemann, J. R., Ruland, J., Scheel, C., Lenz, P., Ott, G., et al. (2016) · Oncogene · doi:10.1038/onc.2015.493 · Cited by 48
García‐Fuentes, E., Murri, M., Garrido‐Sánchez, L., García‐Serrano, S., García‐Almeida, J. M., Moreno‐Santos, I., Tinahones, F. J., & Macías‐González, M. (2009) · Obesity · doi:10.1038/oby.2009.314 · Cited by 47
Interplay between SOX9, β-catenin and PPARγ activation in colorectal cancer
Panza, A., Pazienza, V., Ripoli, M. C., Benegiamo, G., Gentile, A., Valvano, M. R., Augello, B., Merla, G., Prattichizzo, C., Tavano, F., et al. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.04.004 · Cited by 47
Wnt/β-catenin signaling plays a distinct role in methyl gallate–mediated inhibition of adipogenesis
Jeon, M., Rahman, N., & Kim, Y. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.08.178 · Cited by 46
Nanomedicines of Hedgehog Inhibitor and PPAR-γ Agonist for Treating Liver Fibrosis
Kumar, V., Mundra, V., & Mahato, R. I. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1239-5 · Cited by 45
Differential effect of NF‐κB activity on β‐catenin/Tcf pathway in various cancer cells
Cho, H. H., Song, J. S., Yu, J. M., et al. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.01.029 · Cited by 42
Down-regulation of peroxisome proliferator-activated receptor gamma in human cervical carcinoma
Jung, T.-I., Baek, W., Suh, S., Jang, B., Song, D., Bae, J., Kwon, K., Bae, J.-H., Cha, S.-D., Bae, I., et al. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.01.019 · Cited by 42
Zhang, X., Ke, X., Pu, Q., Yuan, Y., Yang, W., Luo, X., Jiang, Q., Hu, X., Gong, Y., Tang, K., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7538 · Cited by 41
Kim, Y.-H., Woo, K. J., Lim, J. H., Kim, S., Lee, T. J., Jung, E. M., Lee, J.-M., Park, J., & Kwon, T. K. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.01.159 · Cited by 40
Edwards, I. J., Berquin, I. M., Sun, H., O’Flaherty, J. T., Daniel, L. W., Thomas, M. J., Rudel, L. L., Wykle, R. L., & Chen, Y. Q. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1357 · Cited by 40
Guo, F., Ren, X., Dong, Y., Hu, X., Xu, D., Zhou, H., Meng, F., Tian, W., & Zhao, Y. (2016) · Gene · doi:10.1016/j.gene.2016.03.003 · Cited by 40
Ohta, T., Elnemr, A., Yamamoto, M., Ninomiya, I., Fushida, S., Nishimura, G., Fujimura, T., Kitagawa, H., Kayahara, M., Shimizu, K., et al. (2002) · International Journal of Oncology · doi:10.3892/ijo.21.1.37 · Cited by 39
Liu, J., Dai, X., Xu, Y., Liu, P., Zhang, Y., Liu, X., Fang, Z., Lin, D.-J., Xiao, R., Huang, R., et al. (2011) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-011-9253-x · Cited by 38
Liu, L., Yang, Z., Xu, Y., Li, J., Xu, D., Zhang, L., Sun, J., Xia, S., Zou, F., & Liu, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073038 · Cited by 36
CTNNB1, AXIN1 and APC expression analysis of different medulloblastoma variants
da Silva, R., Marie, S. K. N., Uno, M., Matushita, H., Wakamatsu, A., Rosemberg, S., & Oba‐Shinjo, S. M. (2013) · Clinics · doi:10.6061/clinics/2013(02)oa08 · Cited by 34
Fujita, M., Yagami, T., Fujio, M., Tohji, C., Takase, K., Yamamoto, Y., Sawada, K., Yamamori, M., & Okamura, N. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.08.010 · Cited by 34
Padhi, S., Saha, A., Kar, M., Ghosh, C., Adhya, A. K., Baisakh, M. R., Mohapatra, N., Venkatesan, S., Hande, M. P., & Banerjee, B. (2015) · Journal of Cancer · doi:10.7150/jca.9558 · Cited by 34
Sharma, A., Rajappa, M., Satyam, A., & Sharma, M. (2010) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-010-0437-2 · Cited by 33
Chen, F., Kim, E. S., Wang, C., & Harrison, L. E. (2005) · Cellular Signalling · doi:10.1016/j.cellsig.2005.03.012 · Cited by 32
Park, H. J., Yun, J., Jang, S.-H., Kang, S. N., Jeon, B., Ko, Y., Kim, H.-D., Won, C., Kim, G. S., & Cho, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105809 · Cited by 32
Terrasi, M., Bazan, V., Caruso, S., Insalaco, L., Amodeo, V., Fanale, D., Corsini, L. R., Contaldo, C., Mercanti, A., Fiorio, E., et al. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.24295 · Cited by 31
Farshbaf, M. J., Ghaedi, K., Shirani, M., & Nasr‐Esfahani, M. H. (2013) · Medical Hypotheses · doi:10.1016/j.mehy.2013.12.012 · Cited by 29
Capaccio, D., Ciccodicola, A., Sabatino, L., Casamassimi, A., Pancione, M., Fucci, A., Febbraro, A., Merlino, A., Graziano, G., & Colantuoni, V. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.01.012 · Cited by 29
PPARγ agonists: Potential treatments for exudative age-related macular degeneration
Vallée, A., Lecarpentier, Y., Guillevin, R., & Vallée, J.-N. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.09.008 · Cited by 29
Self-citationLi, Q., Yan, Z., Li, F., Lu, W., Wang, J., & Guo, C. (2012) · Nanotechnology · doi:10.1088/0957-4484/23/26/265101 · Cited by 28
Lee, S.-Y., Saito, T., Mitomi, H., Hidaka, Y., Murakami, T., Nomura, R., Watanabe, S., & Yao, T. (2015) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-015-1753-4 · Cited by 28
Ren, X., Zheng, D., Guo, F., Liu, J., Zhang, B., Li, H., & Tian, W. (2015) · Medical Oncology · doi:10.1007/s12032-015-0536-8 · Cited by 26
Abdelmaksoud‐Dammak, R., Miladi-Abdennadher, I., Triki, M., Khabir, A., Charfi, S., Ayadi, L., Frikha, M., Sellami‐Boudawara, T., & Mokdad‐Gargouri, R. (2015) · Archives of Medical Research · doi:10.1016/j.arcmed.2015.01.001 · Cited by 24
The role of Wnt signaling pathway in carcinogenesis and implications for anticancer therapeutics
Sheikh, A., Niazi, A. K., Ahmed, M. Z., Iqbal, B., Anwer, S. M. S., & Khan, H. H. (2014) · Hereditary Cancer in Clinical Practice · doi:10.1186/1897-4287-12-13 · Cited by 21
Lecarpentier, Y., Schussler, O., CLAES, V. A., & Vallée, A. (2017) · Nuclear Receptor Research · doi:10.11131/2017/101299 · Cited by 21
Self-citationShim, C. Y., Song, B., Cha, M., Hwang, K., Park, S., Hong, G., Kang, S., Lee, J. E., Ha, J., & Chung, N. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12153 · Cited by 20
Bandino, A., Compagnone, A., Bravoco, V., Cravanzola, C., Lomartire, A., Rossetto, C., Novo, E., Cannito, S., di Bonzo, L. V., Zamara, E., et al. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.01.029 · Cited by 17
Research works printed but not linked: 7
- Yamasaki, 2004, Cytokines regulate fibroblast-like synovial cell differentiation to adipocyte-like cells, Rheumatology (Oxford), 43, 448, 10.1093/rheumatology/keh092 · doi:10.1093/rheumatology/keh092
- He, 2007, Expression of peroxisome proliferator-activated receptor gamma, E-cadherin and matrix metalloproteinases-2 in gastric carcinoma and lymph node metastases, Chin Med J (Engl), 120, 1498, 10.1097/00029330-200709010-00007 · doi:10.1097/00029330-200709010-00007
- Aldred, 2003, Peroxisome proliferator-activated receptor gamma is frequently downregulated in a diversity of sporadic nonmedullary thyroid carcinomas, Oncogene, 22, 3412, 10.1038/sj.onc.1206400 · doi:10.1038/sj.onc.1206400
- Terashita, 2002, Decreased peroxisome proliferator-activated receptor gamma gene expression is correlated with poor prognosis in patients with esophageal cancer, Jpn J Clin Oncol, 32, 238, 10.1093/jjco/hyf056 · doi:10.1093/jjco/hyf056
- Bambury, 2013, Specific PPAR gamma agonists may have different effects on cancer incidence, Annu Oncol Off, 24, 854, 10.1093/annonc/mdt003 · doi:10.1093/annonc/mdt003
- Liu, 2013, Combinational effect of PPARγ agonist and RXR agonist on the growth of SGC7901 gastric carcinoma cells in vitro, Tumour Biol, 34, 2409, 10.1007/s13277-013-0791-2 · doi:10.1007/s13277-013-0791-2
- Kim, 2006, Differential anti-proliferative actions of peroxisome proliferator-activated receptor-gamma agonists in MCF-7 breast cancer cells, Biochem Pharmacol, 72, 530, 10.1016/j.bcp.2006.05.009 · doi:10.1016/j.bcp.2006.05.009
Cited by
PPARs as Metabolic Regulators in the Liver: Lessons from Liver-Specific PPAR-Null Mice
Wang, Y., Nakajima, T., Gonzalez, F. J., & Tanaka, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062061 · Cited by 540
Oxidative Stress: Signaling Pathways, Biological Functions, and Disease
Liu, S., Liu, J., Wang, Y., Deng, F., & Deng, Z. (2025) · MedComm · doi:10.1002/mco2.70268 · Cited by 359
WNT/β-catenin signaling in the development of liver cancers
He, S., & Tang, S. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110851 · Cited by 351
Li, Z., Zhu, S., Liu, Q., Wei, J., Jin, Y., Wang, X., & Zhang, L. (2020) · Environmental Pollution · doi:10.1016/j.envpol.2020.115025 · Cited by 301
Red Beetroot and Betalains as Cancer Chemopreventative Agents
Lechner, J. F., & Stoner, G. D. (2019) · Molecules · doi:10.3390/molecules24081602 · Cited by 122
Metadata
- Authors
- Vallée, A., & Lecarpentier, Y.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2018-04-13
- Volume
- 9
- Pages
- 745-745
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2797499614
- Cited by
- 374
- References
- 284
- FWCI
- 9.73
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.